Comparing Cost-Effectiveness Results for a Vaccine Across Different Countries Worldwide: What Can We Learn?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparing Cost-Effectiveness Results for a Vaccine Across Different Countries Worldwide: What Can We Learn?
Authors
Keywords
Budget optimisation, Cost-effectiveness analysis, Cost neutral price, Economic evaluation, Gross domestic product per capita, Maximum price, Return on investment, Threshold value, Vaccination
Journal
ADVANCES IN THERAPY
Volume 31, Issue 10, Pages 1095-1108
Publisher
Springer Nature
Online
2014-10-20
DOI
10.1007/s12325-014-0160-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines
- (2014) A. T. Newall et al. PHARMACOECONOMICS
- Economics of vaccines revisited
- (2013) Maarten J. Postma et al. Human Vaccines & Immunotherapeutics
- Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France
- (2013) Baudouin Standaert et al. Applied Health Economics and Health Policy
- The evolving epidemiology of rotavirus gastroenteritis in central Portugal with modest vaccine coverage
- (2012) Fernanda Rodrigues et al. JOURNAL OF CLINICAL VIROLOGY
- Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program
- (2012) Nadia Demarteau et al. PHARMACOECONOMICS
- The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt
- (2012) Mark P. Connolly et al. PHARMACOECONOMICS
- Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model
- (2012) Mustafa Bakir et al. VACCINE
- Setting Cost-Effectiveness Thresholds As A Means To Achieve Appropriate Drug Prices In Rich And Poor Countries
- (2011) Patricia M. Danzon et al. HEALTH AFFAIRS
- Rotavirus Vaccine RIX4414 (Rotarix™)
- (2011) Greg L. Plosker PHARMACOECONOMICS
- Rotavirus Vaccine RIX4414 (Rotarix™)
- (2011) Greg L. Plosker PHARMACOECONOMICS
- Health economics of rotavirus immunization in Vietnam: Potentials for favorable cost-effectiveness in developing countries
- (2011) Hong-Anh T. Tu et al. VACCINE
- Global impact of rotavirus vaccines
- (2010) Jacqueline E Tate et al. Expert Review of Vaccines
- Is There a Role for Pharmacoeconomics in Developing Countries?
- (2010) Babar Zaheer-Ud-Din et al. PHARMACOECONOMICS
- Economic Costs of Rotavirus Gastroenteritis and Cost‐Effectiveness of Vaccination in Developing Countries
- (2009) Richard D. Rheingans et al. JOURNAL OF INFECTIOUS DISEASES
- The Burden of Hospitalizations and Clinic Visits for Rotavirus Disease in Children Aged
- (2009) Celia C. Carlos et al. JOURNAL OF INFECTIOUS DISEASES
- Cost Effectiveness in Low- and Middle-Income Countries
- (2009) Samuel D. Shillcutt et al. PHARMACOECONOMICS
- Rotavirus gastroenteritis in Norway: Analysis of prospective surveillance and hospital registry data
- (2009) Elmira Flem et al. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
- WHO Guide for standardisation of economic evaluations of immunization programmes
- (2009) Damian G. Walker et al. VACCINE
- Cost-Effectiveness Analysis
- (2008) Mendel E Singer PHARMACOECONOMICS
- The cost-utility of rotavirus vaccination with Rotarix™ (RIX4414) in the Netherlands
- (2007) Lucas M.A. Goossens et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started